at MarketWatch.com (Dec 1, 2010)
Specialty pharmaceutical firm Eurand (EURX) agrees to be bought for $12/share in cash by Axcan holdings, a pharma firm focused on gastrointestinal disorders. The $583M deal is a 9% premium to Eurand's close yesterday. (PR)
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs